| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $2,486,650 ) |
| | 2026 | 2026 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902 | MONTGOMERY | USA | R44AI186871 | AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy | 000 | 2 | NIH | 8/14/2026 | $976,628 |
| | 2026 | 2026 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902 | MONTGOMERY | USA | R01AI180651 | Targeting Feedback Circuitry for Antiviral Therapy | 000 | 3 | NIH | 12/10/2025 | $1,510,374 |
| | 2026 | 2025 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902 | MONTGOMERY | USA | R37AI109593 | Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics | 000 | 11 | NIH | 11/30/2025 | $0 |
| | 2026 | 2024 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902 | MONTGOMERY | USA | DP1DA051144 | A Gene Drive Therapy for HIV: Single-Administration Intervention for High-RiskGroups | 000 | 6 | NIH | 8/5/2026 | -$352 |
|
| Issue Date FY: 2025 ( Subtotal = $6,065,334 ) |
| | 2025 | 2025 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902-1643 | MONTGOMERY | USA | R44AI186871 | AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy | 000 | 1 | NIH | 9/10/2025 | $1,004,473 |
| | 2025 | 2025 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902-1643 | MONTGOMERY | USA | R01AI180651 | Targeting Feedback Circuitry for Antiviral Therapy | 001 | 2 | NIH | 12/4/2024 | $1,510,374 |
| | 2025 | 2025 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902-1643 | MONTGOMERY | USA | R37AI109593 | Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics | 003 | 11 | NIH | 4/3/2025 | $1,927,847 |
| | 2025 | 2024 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902-1643 | MONTGOMERY | USA | R37AI109593 | Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics | 001 | 10 | NIH | 12/4/2024 | $905,866 |
| | 2025 | 2024 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902 | MONTGOMERY | USA | R43AI184267 | Synthetic RNA sensors to enable high-throughput, quantitative screens for broad-spectrum antivirals | 000 | 1 | NIH | 6/10/2025 | -$65 |
| | 2025 | 2024 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902-1643 | MONTGOMERY | USA | DP1DA051144 | A Gene Drive Therapy for HIV: Single-Administration Intervention for High-RiskGroups | 001 | 6 | NIH | 12/20/2024 | $716,839 |
|
| Issue Date FY: 2024 ( Subtotal = $273,644 ) |
| | 2024 | 2024 | AUTONOMOUS THERAPEUTICS INC | 11808 AUTH LN | SILVER SPRING | MD | 20902-1643 | MONTGOMERY | USA | R43AI184267 | Synthetic RNA sensors to enable high-throughput, quantitative screens for broad-spectrum antivirals | 000 | 1 | NIH | 5/8/2024 | $273,644 |
|
|
